{
    "root": "9fef1c77-9343-4fef-bca3-b4c570627d72",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "PYZCHIVA",
    "value": "20250509",
    "ingredients": [
        {
            "name": "USTEKINUMAB",
            "code": "FU77B4U5Z0",
            "drugbank_id": "https://go.drugbank.com/drugs/DB05679"
        },
        {
            "name": "METHIONINE",
            "code": "AE28F7PNPL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16811"
        }
    ],
    "indications": {
        "text": "pyzchiva human interleukin-12 -23 antagonist indicated treatment : adult patients : moderate severe plaque psoriasis ( pso ) candidates phototherapy systemic therapy . ( 1.1 ) active psoriatic arthritis ( psa ) . ( 1.2 ) moderately severely active crohn 's disease ( cd ) . ( 1.3 ) moderately severely active ulcerative colitis . ( 1.4 ) pediatric patients 6 years older : moderate severe plaque psoriasis , candidates phototherapy systemic therapy . ( 1.1 ) active psoriatic arthritis ( psa ) . ( 1.2 )",
        "doid_entities": [
            {
                "text": "psoriasis (DOID:8893)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8893"
            },
            {
                "text": "psoriatic arthritis (DOID:9008)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9008"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "ulcerative colitis (DOID:8577)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8577"
            },
            {
                "text": "colitis (DOID:0060180)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060180"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe plaque psoriasis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_247353"
            }
        ]
    },
    "contraindications": {
        "text": "psoriasis adult subcutaneous recommended ( 2.1 ) : weight range ( kilograms ) recommended less equal 100 kg 45 mg administered subcutaneously initially 4 weeks later , followed 45 mg administered subcutaneously every 12 weeks greater 100 kg 90 mg administered subcutaneously initially 4 weeks later , followed 90 mg administered subcutaneously every 12 weeks psoriasis pediatric patients ( 6 17 years old ) subcutaneous recommended ( 2.1 ) : weight-based dosing recommended initial dose , 4 weeks later , every 12 weeks thereafter . weight range ( kilograms ) dose less 60 kg 0.75 mg/kg 60 kg 100 kg 45 mg greater 100 kg 90 mg psoriatic arthritis adult subcutaneous recommended ( 2.2 ) : recommended 45 mg administered subcutaneously initially 4 weeks later , followed 45 mg administered subcutaneously every 12 weeks . patients co-existent moderate-to-severe plaque psoriasis weighing greater 100 kg , recommended 90 mg administered subcutaneously initially 4 weeks later , followed 90 mg administered subcutaneously every 12 weeks . psoriatic arthritis pediatric ( 6 17 years old ) subcutaneous recommended ( 2.2 ) : weight-based dosing recommended initial dose , 4 weeks later , every 12 weeks thereafter . weight range ( kilograms ) dose less 60 kg 0.75 mg/kg 60 kg 45 mg greater 100 kg co-existent moderate-to-severe plaque psoriasis 90 mg crohn 's disease ulcerative colitis initial adult intravenous recommended ( 2.3 ) : single intravenous infusion using weight-based dosing : weight range ( kilograms ) dose 55 kg 260 mg ( 2 vials ) greater 55 kg 85 kg 390 mg ( 3 vials ) greater 85 kg 520 mg ( 4 vials ) crohn 's disease ulcerative colitis maintenance adult subcutaneous recommended ( 2.3 ) : subcutaneous 90 mg dose 8 weeks initial intravenous dose , every 8 weeks thereafter .",
        "doid_entities": [
            {
                "text": "psoriasis (DOID:8893)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8893"
            },
            {
                "text": "psoriatic arthritis (DOID:9008)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9008"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "ulcerative colitis (DOID:8577)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8577"
            },
            {
                "text": "colitis (DOID:0060180)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060180"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe plaque psoriasis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_247353"
            }
        ]
    },
    "warningsAndPrecautions": "pyzchiva ( ustekinumab-ttwe ) injection clear , colorless light yellow , sterile preservative-free solution . supplied individually packaged , single-dose prefilled syringe single-dose vial . subcutaneous prefilled syringes 45 mg/0.5 ml ( ndc 83457-651-01 ) 90 mg/ml ( ndc 83457-652-01 ) prefilled syringe equipped 29 gauge fixed \u00bd inch needle , needle safety guard , needle cover made natural rubber latex . single-dose vial \u2022 45 mg/0.5 ml ( ndc 83457-651-94 ) intravenous infusion single-dose vial \u2022 130 mg/26 ml ( 5 mg/ml ) ( ndc 83457-654-94 ) storage stability store pyzchiva vials , prefilled syringes refrigerated 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) . store pyzchiva vials upright . keep product original carton protect light time . freeze . shake . needed , individual prefilled syringes may stored room temperature 30\u00b0c ( 86\u00b0f ) maximum single period 35 days original carton protect light . used within 35 days room temperature storage , discard prefilled syringe . prefilled syringe may returned refrigerator one time maximum 60 days . used within 60 days , discard prefilled syringe . record date prefilled syringe removed returned refrigerator carton space provided . pyzchiva expiration date carton prefilled syringe .",
    "adverseReactions": "pyzchiva contraindicated patients clinically significant hypersensitivity ustekinumab products excipients pyzchiva [ ( 5.5 ) ] .",
    "indications_original": "PYZCHIVA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis . ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 )",
    "contraindications_original": "Psoriasis Adult Subcutaneous Recommended Dosage ( 2.1 ): Weight Range (kilograms) Recommended Dosage less than or equal to 100 kg 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks greater than 100 kg 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks Psoriasis Pediatric Patients (6 to 17 years old) Subcutaneous Recommended Dosage ( 2.1 ): Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter. Weight Range (kilograms) Dose less than 60 kg 0.75 mg/kg 60 kg to 100 kg 45 mg greater than 100 kg 90 mg Psoriatic Arthritis Adult Subcutaneous Recommended Dosage ( 2.2 ): The recommended dosage is 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks. For patients with co-existent moderate-to-severe plaque psoriasis weighing greater than 100 kg, the recommended dosage is 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks. Psoriatic Arthritis Pediatric (6 to 17 years old) Subcutaneous Recommended Dosage ( 2.2 ) : Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter. Weight Range (kilograms) Dose less than 60 kg 0.75 mg/kg 60 kg or more 45 mg greater than 100 kg with co-existent moderate-to-severe plaque psoriasis 90 mg Crohn's Disease and Ulcerative Colitis Initial Adult Intravenous Recommended Dosage ( 2.3 ) : A single intravenous infusion using weight-based dosing: Weight Range (kilograms) Dose up to 55 kg 260 mg (2 vials) greater than 55 kg to 85 kg 390 mg (3 vials) greater than 85 kg 520 mg (4 vials) Crohn's Disease and Ulcerative Colitis Maintenance Adult Subcutaneous Recommended Dosage ( 2.3 ) : A subcutaneous 90 mg dose 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.",
    "warningsAndPrecautions_original": "PYZCHIVA (ustekinumab-ttwe) injection is a clear, colorless to light yellow, sterile and preservative-free solution. It is supplied as individually packaged, single-dose prefilled syringe or single-dose vial.\n                  \n                     For Subcutaneous Use\n                  \n                  \n                     Prefilled Syringes\n                  \n                  \n                     45 mg/0.5 mL (NDC 83457-651-01)\n                     90 mg/mL (NDC 83457-652-01)\n                  \n                  Each prefilled syringe is equipped with a 29 gauge fixed \u00bd inch needle, a needle safety guard, and a needle cover that is not made with natural rubber latex.\n                  \n                  \n                     Single-dose Vial\n                  \n                  \u2022\u00a0 \u00a045 mg/0.5 mL (NDC 83457-651-94)\n                  \n                  \n                     For Intravenous Infusion\n                  \n                  \n                     Single-dose Vial\n                  \n                  \u2022 130 mg/26 mL (5 mg/mL) (NDC 83457-654-94)\n                  \n                     Storage and Stability\n                  \n                  Store PYZCHIVA vials, and prefilled syringes refrigerated between 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). Store PYZCHIVA vials upright. Keep the product in the original carton to protect from light until the time of use. Do not freeze. Do not shake.\n                  If needed, individual prefilled syringes may be stored at room temperature up to 30\u00b0C (86\u00b0F) for a maximum single period of up to 35 days in the original carton to protect from light. If not used within 35 days of room temperature storage, discard the prefilled syringe. The prefilled syringe may be returned to the refrigerator one time only for a maximum of 60 days. If not used within 60 days, discard the prefilled syringe. Record the date when the prefilled syringe is removed from and returned to the refrigerator on the carton in the space provided.\n                  Do not use PYZCHIVA after the expiration date on the carton or on the prefilled syringe.",
    "adverseReactions_original": "PYZCHIVA is contraindicated in patients with clinically significant hypersensitivity to ustekinumab products or to any of the excipients in PYZCHIVA [see Warnings and Precautions (5.5)].",
    "drug": [
        {
            "name": "PYZCHIVA",
            "drugbank_id": "https://go.drugbank.com/drugs/DB05679"
        }
    ]
}